中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

微血管侵犯分级对肝细胞癌行根治性肝切除术后早期复发的预测价值

何旭昶 安文慧 曾庆彬 龙奎 董文志 杨婧 莫小华

引用本文:
Citation:

微血管侵犯分级对肝细胞癌行根治性肝切除术后早期复发的预测价值

DOI: 10.3969/j.issn.1001-5256.2020.08.016
基金项目: 

科技人才和平台计划(2019IC034); 

详细信息
  • 中图分类号: R735.7

Value of microvascular invasion grade in predicting the early recurrence of hepatocellular carcinoma after radical hepatectomy

Research funding: 

 

  • 摘要:

    目的回顾性分析肝细胞癌术后患者的预后,研究微血管侵犯(MVI)分级与经典临床肿瘤分期(TNM分期、BCLC分级)在肝细胞癌术后早期复发预测价值上的差异,进而探讨MVI分级的临床价值。方法选取2015年12月-2017年12月在昆明医科大学第二附属医院肝胆外科进行根治性肝切除术治疗的HCC患者共100例,根据随访2年后的结果,分为复发组(n=49)和未复发组(n=51)。比较2组患者的实验室指标及MVI分级情况;比较MVI分级、TNM分期和BCLC分级在预测患者术后2年无复发生存期的价值。符合正态分布计量资料2组间比较采用t检验;不符合正态分布的计量资料2组间比较采用Mann-Whitney U检验。计数资料2组间非等级资料比较采用χ2检验,等级资料比较采用Mann-Whitney U检验; 3组间比较采用Kruskai-Wallis H检验,进一步两两比较采用Bonferroni法。Kaplan-Meier法绘制生存曲线,log-rank检验进行比较。通过rms包计算一致性指数进行各临床病理分期预测价值的比较。结果与未复发组比较,复发组患者AFP水平更高(Z=0.099,P<0....

     

  • [1] DE’ANGELIS N,LANDI F,CARRA MC,et al. Managements of recurrent hepatocellular carcinoma after liver transplantation:A systematic review[J]. World J Gastroenterol,2015,21(39):11185-11198.
    [2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
    [3] POON RT,FAN ST,TSANG FH,et al. Locoregional therapies for hepatocellular carcinoma:A critical review from the surgeon's perspective[J]. Ann Surg,2002,235(4):466-486.
    [4] WANG FS,FAN JG,ZHANG Z,et al. The global burden of liver disease:The major impact of China[J]. Hepatology,2014,60(6):2099-2108.
    [5] GARCEA G,ONG SL,MADDERN GJ. Predicting liver failure following major hepatectomy[J]. Dig Liver Dis,2009,41(11):798-806.
    [6] DONG JH,HUANG ZQ. Precise hepatectomy:A new concept of liver surgery in the 21st century[J]. Chin J Surg,2009,47(21):1601-1605.(in Chinese)董家鸿,黄志强.精准肝切除———21世纪肝脏外科新理念[J].中华外科杂志,2009,47(21):1601-1605.
    [7] CHEN K,YANG HJ,DENG XF,et al. Risk factors of primary hepatocellular carcinoma patients early term recurrence after radical resection and prediction model establishment[J]. Chin J Cancer Prev Treat,2018,25(5):48-52.(in Chinese)陈凯,杨洪吉,邓小凡,等.肝癌根治性切除术后早期复发危险因素分析及预测模型构建[J].中华肿瘤防治杂志,2018,25(5):48-52.
    [8] ROAYAIE S,BLUME IN,THUNG SN,et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma[J]. Gastroenterology,2009,137(3):850-855.
    [9] ZHANG XJ,WANG L. Clinical significance of microvascular invasion in the comprehensive diagnosis and treatment of hepatocellular carcinoma[J]. Chin J Dig Surg,2019,18(4):336-341.(in Chinese)张小晶,王琳.微血管侵犯在肝癌综合诊断与治疗中的临床意义[J].中华消化外科杂志,2019,18(4):336-341.
    [10] ZHANG XJ,LIU J,LIU K,et al. Effect of microvascular invasion on prognosis of patients with hepatocellular carcinoma after hepatectomy[J]. Chin J Dig Surg,2018,17(5):483-487.(in Chinese)张小晶,刘静,刘坤,等.微血管侵犯对肝癌肝切除术后预后的影响[J].中华消化外科杂志,2018,17(5):483-487.
    [11] Chinese Society of Liver Cancer,Chinese Anti-Cancer Association; Liver Cancer Study Group,Chinese Society of Hepatology,Chinese Medical Association; Chinese So-ciety of Pathology,Chinese Anti-Cancer Association,etal. Evidencebased practice guidelines for the standardized pathological diagnosis of primary liver cancer in China(2015 update)[J]. J Clin Hepatol,2015,31(6):833-839.(in Chinese)中国抗癌协会肝癌专业委员会,中华医学会肝病会分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].临床肝胆病杂志,2015,31(6):833-839.
    [12] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
    [13] CHUN YS,PAWLIK TM,VAUTHEY JN. 8th edition of the AJCC cancer staging manual:Pancreas and hepatobiliary cancers[J]. Ann Surg Oncol,2018,25(4):845-847.
    [14] RODRGUEZ-PERLVAREZ M,LUONG TV,ANDREANA L,et al. A systematic review of microvascular invasion in hepatocellular carcinoma:Diagnostic and prognostic variability[J].Ann Surg Oncol,2013,20(1):325-339.
    [15] WANG J,MA JL. Prognostic factors of liver cancer[J]. Chin J Pract Surg,2015,24(2):270-274.(in Chinese)汪晋,马金良.肝癌预后相关影响因素[J].中国普通外科杂志,2015,24(2):270-274.
    [16] FENG LH,DONG H,LAU WY,et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,2017,143(2):293-303.
    [17] ZHAO H,CHEN C,FU X,et al. Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocell ular carcinoma after resection[J]. Oncotarget,2017,8(3):5474-5486.
    [18] SUN Z,WANG ZN,ZHU Z,et al. Evaluation of the seventh edition of American Joint Committee on Cancer TNM staging system for gastric cancer:Results from a Chinese monoinstitutional study[J]. Ann Surg Oncol,2012,19(6):1918-1927.
    [19] JING JS,KANG W,ZHANG CZ,et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion[J]. Ann Surg Oncol,2016,23(4):1344-1351.
    [20] PENG ZW,CHEN SL,XIAO H,et al. Microvascular invasion as a predictor of response to treatment with sorafenib and transarterial chemoembolization for recurrent intermediatestage hepatocellular carcinoma[J]. Radiology,2019,292(1):237-247.
    [21] SHI FX,ZHOU Z,HUANG XZ,et al. Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience[J]. Future Oncol,2019,15(17):2041-2051.
  • 加载中
计量
  • 文章访问数:  1630
  • HTML全文浏览量:  24
  • PDF下载量:  225
  • 被引次数: 0
出版历程
  • 出版日期:  2020-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回